MEDIA, Pa., March 8 /PRNewswire/ -- Early detection of the onset of menopause is an important first step to improved quality of life and long term health for the millions of American women who enter menopause annually. In the medical community, it is a well-known fact that menopausal women are at a greater risk for diseases such as osteoporosis and cardiovascular disease. However, a national survey of women conducted for Synova Healthcare on the subject showed that more than half of all women were simply not aware of these particular risks. The study also showed that the majority of women are still prolonging diagnosis and not taking precautionary steps to improve their quality of life.
Dr. Laura Corio, Ob/Gyn at Mt. Sinai Medical Center and best-selling author of The Change Before The Change, states “early confirmation of menopause is important as it provides women with a sense of control and allows them to be proactive about countering the effects of menopause. By diagnosing the onset of menopause early, treatment can be sought for the relief of stressful symptoms. An early and accurate diagnosis can improve long-term health and offer peace of mind that symptoms, such as mood changes and feelings of anxiety, are associated with menopause and not some other potential illness.”
A simple at-home urine test can now allow women to accurately check for the onset of menopause in the privacy of their own home. Menocheck(R), the first over-the-counter menopause indicator test is now widely available at fine retailers, including Walgreens’ locations. The easy-to-use midstream wand offers women the convenience of a one-step test, and an attractive, non-invasive alternative to clinical blood testing for initial menopause screenings.
At-home testing with Menocheck(R) can empower women by helping them understand when they have entered the menopausal stage of their lives, so that they can then discuss the best course of action with their healthcare provider. Eighty per cent of perimenopausal women surveyed confirmed they would consider using an at-home self-detection test, with the majority of them citing convenience and cost as the two biggest benefits. It is evident that self-diagnostic tests like Menocheck(R), used in conjunction with a follow-up visit to a doctor, can offer a simple solution for most women.
“With Americans’ increasing desire to be proactive about health issues, self-diagnostic tests are proving to satisfy an important unmet need among consumers”, says Stephen King, CEO of Synova Healthcare, Inc., distributors of Menocheck(R). “As with other self-help alternatives, consumers are encouraged to always discuss their results with their doctors to help develop a collaborative, healthy-lifestyle plan.” He also explained that an actual Menocheck(R) user likely put is best when she said “Menocheck(R) doesn’t replace going to my doctor, but it helps me be prepared for the next phase of my life”.
About Menocheck(R):
Non-invasive and similar to an at-home pregnancy test in design, Menocheck(R) works by measuring the levels of follicle stimulating hormone (FSH) in the urine. FSH can fluctuate, however, as women enter menopause, FSH levels gradually rise and stay permanently higher once menopause has set in. Menocheck(R) is FDA approved. Each package includes two test devices and simple-to-follow instructions, and when used as directed has been shown to be 99% accurate. Menocheck(R) typically retails for $19.99 and is now widely available at fine retailers nationwide. For more information about menopause and Menocheck(R) consumers can visit http://www.menocheck.com/ .
About Synova Healthcare, Inc.:
Synova Healthcare Inc., a wholly owned subsidiary of Synova Healthcare Group, Inc (SNVH), distributes rapid, non-invasive medical diagnostics both over-the-counter (OTC) and direct to healthcare providers at the point of care (POC). The company’s products improve human health and quality of life by providing early and accurate awareness of the onset of certain medical conditions.
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends”, “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.
Corporate Contact Information: Synova Healthcare, Inc 1400 N. Providence Road, Ste. 6010 Media, PA 19063 Tel: 610-565-7080 Fax: 610-565-7081
(*) The national study was conducted by Innovative Media Research through telephone and internet interviews among a representative sample of American women, aged 36 to 60. The interviews with 1,473 women were conducted between October 13 and 20, 2003. The data is precise 99% of the time, within +/- 3.4%.
(+) 99% accuracy agreement in studies conducted with Consumers/Lay Users.
Synova Healthcare, Inc.
CONTACT: Synova Healthcare, +1-610-565-7080, or fax, +1-610-565-7081
Web site: http://www.menocheck.com/